Navigation Links
Novel therapeutic targets identified for small cell lung cancer
Date:9/6/2012

PHILADELPHIA Newly discovered molecular differences between small cell lung cancer and nonsmall cell lung cancer have revealed PARP1 and EZH2 as potential therapeutic targets for patients with small cell lung cancer, according to the results of a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

Currently, small cell lung cancer accounts for about 15 percent of lung cancer diagnoses in the United States. Patients with the disease will initially respond to chemotherapy, but almost all will have disease recurrence within a couple of months, according to Lauren A. Byers, M.D., assistant professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.

"Unlike nonsmall cell lung cancer [NSCLC], where there have been new targeted drugs developed in the last ten years, the only currently approved treatments for small cell lung cancer are cytotoxic chemotherapies," Byers said. "Because most targeted therapies directly act on proteins, identifying if certain proteins are overexpressed in small cell lung cancer could have therapeutic applications."

In order to identify molecular differences between NSCLC and the more aggressive small cell lung cancer, Byers and colleagues used tools called reverse phase protein arrays. These allow the examination of the expression of about 200 proteins that are in key signaling pathways known to be involved in driving cancer growth.

"We discovered that small cell lung cancer and NSCLC have dramatically different protein profiles in terms of which proteins are 'turned on' and are driving the behavior of these cancers," Byers said. "In small cell lung cancer, proteins that were present at higher levels included several DNA repair proteins such as PARP1 and a protein involved in cancer stem cell renewal, EZH2."

PARP1 was further evaluated as a target for treatment of small cell lung cancer because there are several PARP inhibitors in advanced-stage clinical trials for other tumor types such as breast and ovarian cancers. Moreover, small cell lung cancer is sensitive to platinum-based chemotherapy, and PARP inhibitors have shown increased activity when used on other platinum-sensitive tumors.

Two PARP inhibitors were tested on small cell lung cancer cell lines alone and in combination with standard frontline chemotherapeutics, cisplatin and etoposide, or another commonly used chemotherapeutic, irinotecan. The inhibitors slowed the growth of small cell lung cancer cells, but not non-neuroendocrine NSCLC cells, according to the study. In addition, levels of PARP1 expression directly correlated with PARP inhibitor sensitivity.

As with many targeted drugs, it is possible that combining PARP inhibitors with other targeted drugs may significantly improve efficacy, according to Byers.

"Our next step is to begin to examine the use of PARP inhibitors in combination with other drugs in preclinical and clinical investigations of small cell lung cancer," she said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Novel technique demonstrates interactions between malaria parasite and HIV
2. Genetic analyses reveal novel mutations as causes of startle disease
3. UNC team describes novel inflammatory protein function
4. Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
5. LA BioMed investigator, Dr. Yutaka Niihara, developing novel cellular therapy
6. New method to find novel connections from gene to gene, drug to drug and between scientists
7. Novel pig model may be useful for human cancer studies
8. Novel anti-malarial drug target identified
9. ICAP study uses novel incentive to encourage HIV patient care and treatment
10. Researchers to use novel metabolomics technology for COPD
11. Cell differentiation as a novel strategy for the treatment of an aggressive type of skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... ... May 30, 2016 , ... As the CDC relaxes ... children and their efforts to keep their households lice free. , According to ... enacting new policies that keep kids in the classroom despite the fact that they ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... of FCPX," said Christina Austin - CEO of Pixel Film Studios. , ... Final Cut Pro X. Choose from abstract transitions to more simple wipes with ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... announced today the publication of an original infographic, " Health Benefits Reimbursement Compliance ... professionals understand how Zane Benefits complies with various federal regulations and reforms. , ...
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin Institute officially starts the ... special intensive summer training camp starts on June 17th on Shaolin Institute Atlanta ... children a fun and unique experience with an opportunity to learn KungFu martial ...
(Date:5/30/2016)... ... May 30, 2016 , ... Another ER facility operated by First Choice ... Legacy Drive, Plano, TX and is open 24 hours daily. , First Choice Emergency ... medical open house. The Jasper High School band entertained attendees and accepted First Choice ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 Eye ... parents of premature babies to seek an eye examination ... blinding condition     Moorfields Eye Hospital ... in London , has identified premature babies as ... problems, because of their particular vulnerability to retinopathy of prematurity (ROP). ...
(Date:5/27/2016)...  A new study highlights the necessity of health literacy within the technology advancement ... College of Radiology , a majority of oncology patients undergo imaging screenings without understanding ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... Israel , May 27, 2016 ... of the Dario™ Diabetes Management Tool, today announced that the ... at the Marcum MicroCap Conference being held June 1-2 in ... Micro Invitational, being held June 7-9 in Los ... Ben-David will discuss recent corporate and operational milestones, including the ...
Breaking Medicine Technology: